These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 38854928)
21. Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid Analgesics. Cohen JP; Mendoza M; Roland C Clin Ther; 2018 Feb; 40(2):334-344. PubMed ID: 29398162 [TBL] [Abstract][Full Text] [Related]
22. Emerging Trends in Abuse-Deterrent Formulations: Technological Insights and Regulatory Considerations. Rana D; Salave S; Benival D Curr Drug Deliv; 2022; 19(8):846-859. PubMed ID: 34879799 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD). Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548 [TBL] [Abstract][Full Text] [Related]
24. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Hale ME; Moe D; Bond M; Gasior M; Malamut R Pain Manag; 2016 Oct; 6(5):497-508. PubMed ID: 27050830 [TBL] [Abstract][Full Text] [Related]
25. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program. Vosburg SK; Haynes C; Besharat A; Green JL Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1044-1052. PubMed ID: 28653782 [TBL] [Abstract][Full Text] [Related]
26. Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters? Salwan AJ; Hagemeier NE; Harirforoosh S Clin Drug Investig; 2018 Jul; 38(7):573-577. PubMed ID: 29651781 [TBL] [Abstract][Full Text] [Related]
27. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations. Gasior M; Bond M; Malamut R Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680 [TBL] [Abstract][Full Text] [Related]
28. Application of Hot Melt Extrusion Technology in the Development of Abuse-Deterrent Formulations: An Overview. Butreddy A; Nyavanandi D; Narala S; Austin F; Bandari S Curr Drug Deliv; 2021; 18(1):4-18. PubMed ID: 32811398 [TBL] [Abstract][Full Text] [Related]
29. Oral Human Abuse Potential of Oxycodone DETERx Kopecky EA; Fleming AB; Levy-Cooperman N; O'Connor M; M Sellers E J Clin Pharmacol; 2017 Apr; 57(4):500-512. PubMed ID: 27669664 [TBL] [Abstract][Full Text] [Related]
30. Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice. Lee YH; Brown DL; Chen HY Pain Physician; 2017 Nov; 20(7):E1003-E1023. PubMed ID: 29149148 [TBL] [Abstract][Full Text] [Related]
31. In Vitro Drug Release After Crushing: Evaluation of Xtampza Mayock SP; Saim S; Fleming AB Clin Drug Investig; 2017 Dec; 37(12):1117-1124. PubMed ID: 28940174 [TBL] [Abstract][Full Text] [Related]
32. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose? Bannwarth B Drugs; 2012 Sep; 72(13):1713-23. PubMed ID: 22931520 [TBL] [Abstract][Full Text] [Related]
34. Use of prescription opioids with abuse-deterrent technology to address opioid abuse. Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694 [TBL] [Abstract][Full Text] [Related]
35. Abuse-Deterrent Opioids: A Survey of Physician Beliefs, Behaviors, and Psychology. Dasgupta N; Brown JR; Nocera M; Lazard A; Slavova S; Freeman PR Pain Ther; 2022 Mar; 11(1):133-151. PubMed ID: 34870790 [TBL] [Abstract][Full Text] [Related]
36. Abuse-deterrent opioid analgesics: a guide for clinicians. Carinci AJ Pain Manag; 2020 Jan; 10(1):55-62. PubMed ID: 31916895 [TBL] [Abstract][Full Text] [Related]
37. Matching study design to prescribing intention: The prevalent new-user design for studying abuse-deterrent formulations of opioids. DiPrete BL; Oh G; Moga DC; Dasgupta N; Slavova S; Slade E; Delcher C; Pence BW; Ranapurwala SI Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5805. PubMed ID: 38720402 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index-Multimedia Version (ASI-MV). Vosburg SK; Beaumont J; Dailey-Govoni ST; Butler SF; Green JL Pain Med; 2020 Sep; 21(9):1891-1901. PubMed ID: 31617931 [TBL] [Abstract][Full Text] [Related]
39. Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product. Pergolizzi JV; Taylor R; LeQuang JA; Raffa RB J Pain Res; 2018; 11():301-311. PubMed ID: 29445297 [TBL] [Abstract][Full Text] [Related]
40. Application of hot-melt extrusion technology in immediate-release abuse-deterrent formulations. Wening K; Schwier S; Stahlberg HJ; Galia E J Opioid Manag; 2017; 13(6):473-484. PubMed ID: 29308593 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]